Year: 2026
Type: article
Abstract: Stroke is the most common cause of new-onset seizures and epilepsy in the older population, which is associated with increased morbidity and mortality. Post-stroke seizures (PSS) are traditionally divided into early and late seizures, occurring before and after 7 days post-stroke, respectively. A single late seizure is sufficient to diagnose post-stroke epilepsy. This narrative review discusses approaches to diagnosing and treating PSS, as well as the various pharmacological agents available. Although current evidence is limited, we suggest that levetiracetam and lamotrigine may be preferred agents for preventing acute seizure recurrence. Statins, GLP-1 agonists, eslicarbazepine, perampanel, and losartan have not been evaluated yet and need further study on their ability to prevent first-time seizures in stroke patients. While clinical trials of antiseizure medications can be costly, further research into biomarkers of epileptogenesis could facilitate more feasible clinical trials to enhance the evidence base for antiseizure medications in post-stroke seizures and epilepsy.
Source: Frontiers in Neurology
Institutions: University of Cambridge, Yale University, Paracelsus Medical University, Christian Doppler Klinik, University of Glasgow, Lancaster University, Sahlgrenska University Hospital, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Shimane University, National Cerebral and Cardiovascular Center, University of California, Los Angeles
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7119188064